Phase II Study of First‐Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma

LESSONS LEARNED. Trebananib leveraging anti‐angiogenic mechanism that is distinct from the classic sorafenib anti‐vascular endothelial growth factor inhibition did not demonstrate improved progression‐free survival at 4 months in patients with advanced hepatocellular carcinoma (HCC). In support of p...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Abou‐Alfa, Ghassan K., Blanc, Jean‐Frederic, Miles, Steven, Ganten, Tom, Trojan, Jörg, Cebon, Jonathan, Liem, Andre K., Lipton, Lara, Gupta, Charu, Wu, Benjamin, Bass, Michael, Hollywood, Ellen, Ma, Jennifer, Bradley, Margaret, Litten, Jason, Saltz, Leonard B.
Format: Artigo
Idioma:Inglês
Publicat: AlphaMed Press 2017
Matèries:
Clinical Trial Results
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5507650/
https://ncbi.nlm.nih.gov/pubmed/28592620
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0058
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars